This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MAFF / Transcription factor MafF · IHC design guide
Design Immunohistochemistry for MAFF
Plan paraffin section IHC for MAFF using the catalog antibody at 2–5 μg/ml (datasheet A07784-2). Compare nuclear staining in placenta, urinary bladder and lymphoid tissues with suitable controls (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MAFF Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in tissue (HPA tissue IHC) | |
| Staining pattern | Nuclear signal in placenta, bladder and lymphoid tissues (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A07784-2) | |
| Positive control | Placenta+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Tissue staining awaits external verification (HPA tissue IHC) | |
| Regulation | Stress response is annotated; intensity effects are unknown (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended MAFF IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with published MAFF staining in human tumors and mouse kidney (PMC7851502; PMC12640644; PMC11155135).
| Sample | Paraffin-embedded human esophageal squamous carcinoma tissue; fixative not specified (datasheet A07784-2) |
| Fixation | Image fixative and duration unreported (datasheet A07784-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A07784-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A07784-2) |
| Primary antibody | Rabbit anti-MAFF, 2-5 μg/ml (datasheet A07784-2) |
| Primary incubation | Overnight at 4 °C (datasheet A07784-2) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A07784-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MAFF-positive staining in trophoblastic cells of placenta (HPA tissue IHC: High). HPA tissue profile: Nuclear expression mainly in the placenta, urinary bladder and gallbladder, and in lymphoid tissues. No signal in the no-primary control. |
💡Decision noteStart with the catalog antibody’s heat-mediated EDTA pH 8.0 retrieval (datasheet: A07784-2); the HCC protocol used citrate and microwave heating (PMC7851502).
Section 2
What Is the Expected MAFF Staining Pattern?
MAFF is a nuclear transcription factor with no transmembrane segment (UniProt Q9ULX9). In paraffin-section IHC, expect nuclear staining in trophoblastic cells of placenta, squamous epithelial cells of tonsil, and urothelial cells of urinary bladder (HPA: High in each). The HPA tissue pattern is Approved, with external verification pending (HPA: reliability).
| Distinct nuclear signal in placental trophoblastic cells, tonsillar squamous epithelium, or bladder urothelium. | This matches the expected compartment (UniProt Q9ULX9: nucleus) and cell-specific High staining (HPA: tissue IHC). Compare signal within identifiable cells, rather than scoring an entire section as uniformly positive. |
| Predominantly cytoplasmic or membranous staining, with little nuclear signal in an expected-positive cell population. | This conflicts with the principal nuclear pattern (UniProt Q9ULX9; HPA: nuclear tissue profile). Check staining controls and morphology before calling it MAFF; HPA separately reports Medium neuropil staining in cerebral cortex. |
| Strong signal in adipocytes or colonic glandular cells while expected-positive nuclei stain weakly. | Those cell types are Not detected in the HPA tissue IHC record. Consider cross-reactivity or endogenous chromogen activity (general IHC practice); a mismatched cell type alone cannot identify which cause applies. |
| Diffuse color across tissue, nuclei, and blank areas, obscuring cellular boundaries. | The distribution cannot support a compartment call (general IHC interpretation). Check a no-primary control for detection background, then review blocking, washes, and chromogen development before scoring MAFF. |
| No nuclear signal in a well-preserved placenta, tonsil, or urinary bladder section. | Each listed cell population has High staining in HPA tissue IHC. Check tissue identity and assay controls, then review the catalog antibody's IHC-P instructions; absence of signal alone does not establish absent MAFF. |
💡Expected MAFF appearanceCall positive when identifiable trophoblastic, tonsillar squamous epithelial, or urothelial cells show clear nuclear staining (HPA: High; UniProt Q9ULX9: nucleus); isolated diffuse or predominantly membranous color is suspect (general IHC interpretation).
| Compartment and protein architecture | MAFF is nuclear, lacks a transmembrane segment, and has a bZIP domain at residues 51–114 (UniProt Q9ULX9). These facts support a nuclear readout; they do not predict a particular antibody epitope. |
| Tissue and cell selection | HPA reports High staining in three named cell populations, Medium staining in appendiceal glandular and lung alveolar cells, and Not detected in colonic glandular cells. Use cell identity when comparing sections (HPA: tissue IHC). |
| Validation and interpretation limit | The tissue IHC record is Approved, pending external verification; CAB025341 has IHC Approved status (HPA: tissue IHC; HPA: antibodies). These labels support use of the reported pattern, without proving every new assay condition. |
| Isoforms and processing | UniProt lists 2 isoforms, a 1–164 chain, and no signal peptide or propeptide (UniProt Q9ULX9). The supplied record gives no isoform-specific staining or antibody epitope; do not assign an isoform from IHC. |
| IF/ICC Q&A | What should IF/ICC show? Mainly nucleoplasmic signal (HPA: supported); an additional mitochondrial location is uncertain (HPA: subcellular). HPA lists HPA055371 as ICC Supported, which does not establish its IHC performance (HPA: antibodies). |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected-positive nuclei are blank. | The run may have a detection or staining problem (general IHC practice); HPA reports High signal in the specified placental, tonsillar, and bladder cells. | Confirm those cells are present, inspect the run's positive control, and follow the catalog antibody's IHC-P instructions. Record the result as unresolved until the assay controls work. |
| Color is mainly outside nuclei in expected-positive cells. | The distribution differs from MAFF's nuclear location (UniProt Q9ULX9) and HPA's nuclear tissue profile; background or an off-target signal is possible. | Inspect a no-primary control and nuclear counterstain, then rescore only cells with clear boundaries. Treat the HPA Medium cortical neuropil observation as a separate tissue finding. |
| Negative-reference cells stain strongly. | Adipocytes and colonic glandular cells are Not detected in HPA tissue IHC; cross-reactivity or endogenous detection activity is possible (general IHC practice). | Compare the same cell types with a no-primary control. If chromogenic background persists, review endogenous enzyme blocking and detection steps (general IHC practice). |
| Diffuse chromogen obscures nuclei. | Excess detection background, insufficient washing, or prolonged chromogen development can obscure localization (general IHC practice). The appearance alone cannot establish MAFF expression. | Check no-primary control staining and review blocking, washes, and development time under the assay instructions; score only after nuclear and cellular boundaries can be distinguished. |
| Only faint signal appears in a candidate tissue. | HPA reports Low staining in hippocampal neuronal and thyroid glandular cells, so faint signal there needs a reliable positive comparison (HPA: tissue IHC). | Run a High-reference tissue and compare matching cell types and nuclear localization. Do not use a Low-reference tissue alone to judge whether the IHC run succeeded. |
| Results differ between IHC and IF/ICC. | HPA assigns separate antibody statuses: CAB025341 is IHC Approved and HPA055371 is ICC Supported (HPA: antibodies). IF's additional mitochondrial location is uncertain (HPA: subcellular). | Interpret each assay with its own antibody validation and controls. Use the supported nucleoplasmic IF pattern for comparison; do not require mitochondrial staining in paraffin-section IHC. |
Experiment evidence
IHC & IF images showing MAFF staining
A07784-2 · IHCIHC analysis of MAFF using anti-MAFF antibody (A07784-2). MAFF was detected in a paraffin-embedded section of human esophageal squamous carc
A07784-2 · IHCIHC analysis of MAFF using anti-MAFF antibody (A07784-2). MAFF was detected in a paraffin-embedded section of human placenta tissue. Heat me
A07784-2 · IFIF analysis of MAFF using anti-MAFF antibody (A07784-2). MAFF was detected in an immunocytochemical section of A431 cells. Enzyme antigen re
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000185022-MAFF/tissue/cerebral+cortex#imid_6494048
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000185022-MAFF/tissue/colon#imid_6488870
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000185022-MAFF/tissue/liver#imid_6488863
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000185022-MAFF/tissue/kidney#imid_6488856
HPA · ICC-IF U-251MGHuman Protein Atlas immunofluorescence, U-251MG, antibody HPA055371; green = MAFF, blue = nucleus, red = microtubules.
HPA · ICC-IF U-251MGHuman Protein Atlas immunofluorescence, U-251MG, antibody HPA055371; green = MAFF, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MAFF IHC & IF
🧪Run placenta first: trophoblastic cells should stain (HPA: High in trophoblastic cells). Use adipose tissue as the negative comparator (HPA: adipocytes Not detected); on the placenta slide, score cells without nuclear signal as internal negative cells only after confirming their identity and staining status.
Positive control tissue: Placenta (Trophoblastic cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MAFF in U-251MG, U2OS, NIH 3T3, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include no-primary (secondary-only), a rabbit IgG isotype control matched to the primary antibody’s clonality, and MAFF-knockout tissue or a validated peptide-block control (catalog caption: rabbit anti-MAFF antibody). For placental chromogenic staining, quench endogenous peroxidase and check for endogenous biotin before biotin–streptavidin detection (catalog caption: biotinylated secondary and SABC–DAB detection).
⚠️Feasibility: A target-specific fixation window and fixation effect are unreported, and the exact selected-SKU paraffin-section caption does not state a fixative. Heat retrieval with EDTA at pH 8.0 was used in that IHC example (catalog caption: EDTA retrieval); whether MAFF staining depends on that retrieval condition is unreported. Frozen sections are not established as easier, while IF/ICC has supported nucleoplasmic localization in HPA images (HPA: nucleoplasm supported); placental endogenous biotin can complicate the caption’s biotin-based detection.
HPA tissue IHC evidence for MAFF
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Placenta | Trophoblastic cells | High | Protein (IHC) | HPA → |
| Tonsil | Squamous epithelial cells | High | Protein (IHC) | HPA → |
| Urinary bladder | Urothelial cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Colon | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Endometrium | Cells in endometrial stroma | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced MAFF IHC Tips
Troubleshoot MAFF staining by checking retrieval, nuclear localisation, cell identity and assay controls before comparing chromogenic IHC scores.
What retrieval should I start with for weak MAFF staining in paraffin sections?
Start with heat-mediated retrieval in EDTA pH 8.0 for paraffin sections (datasheet A07784-2). The selected image used that retrieval, followed by 10% goat serum block and 2 μg/ml primary antibody overnight at 4°C (datasheet A07784-2). If staining is weak, check retrieval heating and cooling consistency across sections before changing antibody concentration (standard IHC practice). Compare any retrieval adjustment on adjacent sections with the same detection and development conditions, because those steps also affect signal (standard IHC practice). Judge improvement by nuclear staining in expected cells and background in a no-primary control (UniProt Q9ULX9 subcellular location; standard IHC practice).
Could fixation explain weak or uneven MAFF staining?
The selected paraffin-section caption does not state a fixative, so MAFF-specific fixation sensitivity is unknown for this antibody (datasheet A07784-2). Record fixative, fixation duration and processing history for each specimen before comparing staining intensity (standard IHC practice). If sections stain unevenly, compare areas with intact morphology and review whether tissue thickness or processing differed (standard IHC practice). Run the same retrieval and detection conditions across a documented positive section and the affected section to isolate a processing effect (datasheet A07784-2; standard IHC practice). Do not assign a fixation-dependent MAFF effect from tissue expression patterns alone (HPA tissue IHC; standard IHC practice).
How should I assess cytoplasmic or mixed MAFF staining?
Score nuclear staining as the primary MAFF signal, consistent with its nuclear annotation and the HPA tissue pattern (UniProt Q9ULX9 subcellular location; HPA tissue IHC). The HPA subcellular record supports nucleoplasmic localisation and lists mitochondrial localisation as uncertain, so cytoplasmic staining needs separate validation (HPA subcellular). Compare nuclear and cytoplasmic signal within the same cell population, alongside a no-primary control and consistent counterstaining (standard IHC practice). Check whether cytoplasmic colour follows tissue edges, damaged regions or pigment before assigning it to MAFF (standard IHC practice). Report mixed staining by compartment rather than combining it into one positive-cell score (standard IHC practice).
Could isoforms or epitope accessibility change the MAFF IHC result?
MAFF has 2 annotated isoforms and a bZIP domain at residues 51–114 (UniProt Q9ULX9). The supplied caption does not identify the antibody epitope or establish isoform-specific recognition, so an IHC difference cannot be assigned to one isoform (datasheet A07784-2). Compare staining after consistent EDTA pH 8.0 retrieval on adjacent sections before interpreting a missing signal as isoform loss (datasheet A07784-2; standard IHC practice). If isoform discrimination matters, obtain epitope mapping and an independently validated isoform-specific assay before making that claim (standard IHC practice). Keep scoring focused on the observed nuclear signal and document any uncertainty about epitope recognition (UniProt Q9ULX9 subcellular location; standard IHC practice).
How can I investigate MAFF localisation with IF alongside this IHC guide?
Treat IF/ICC as a separate assay: the supplied antibody image documents chromogenic paraffin-section IHC, and its caption provides no IF validation (datasheet A07784-2). For IF, pair MAFF with a validated trophoblastic cell marker when examining placenta, where trophoblastic cells show high staining in tissue IHC (HPA tissue IHC; standard IF practice). Choose spectrally separated fluorophores and inspect unstained tissue for autofluorescence before interpreting overlap (standard IF practice). Use permeabilisation appropriate for a nuclear epitope and verify nuclear access with controls; MAFF has no transmembrane segment (UniProt Q9ULX9 topology and subcellular location; standard IF practice). Confirm localisation against a nuclear counterstain without transferring the IHC retrieval settings to IF (standard IF practice).
What should I check when DAB background obscures MAFF-positive nuclei?
The selected IHC image used biotinylated goat anti-rabbit secondary antibody, a streptavidin–biotin complex and DAB (datasheet A07784-2). Check a no-primary section for secondary or detection-system signal, and review the peroxidase block as a general chromogenic IHC step (standard IHC practice). Where diffuse staining persists, compare shorter DAB development, more thorough washes and a matched negative control under otherwise identical conditions (standard IHC practice). The caption used 10% goat serum blocking and 2 μg/ml primary antibody overnight at 4°C; use those recorded conditions as comparison points (datasheet A07784-2). Score nuclear signal only after background is controlled (UniProt Q9ULX9 subcellular location; standard IHC practice).
How should I quantify MAFF across specimens with different cell composition? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and nuclear positivity threshold before scoring, because MAFF tissue staining varies by cell type (HPA tissue IHC; standard IHC practice). Report the percentage of positive nuclei and, when intensity is reproducible, a nuclear H-score calculated as the sum of intensity-category percentages multiplied by their category scores (standard IHC practice). For spatial comparisons, report positive-nucleus density per mm² of viable, annotated tissue (standard IHC practice). Normalise positive counts to all evaluable nuclei in the same cell population, and exclude necrotic or poorly preserved areas (standard IHC practice). Apply one counterstain, imaging and scoring scheme across compared sections (standard IHC practice).
How can I distinguish genuine MAFF staining from a tissue artefact?
A convincing result places signal in nuclei of identifiable cells, consistent with MAFF localisation and the HPA nuclear tissue pattern (UniProt Q9ULX9 subcellular location; HPA tissue IHC). Use the HPA high-staining trophoblastic, squamous epithelial or urothelial populations as reference patterns when those tissues are examined (HPA tissue IHC). Question signal confined to section edges, necrotic areas, pigment or a no-primary control, and check endogenous peroxidase activity in chromogenic sections (standard IHC practice). Cytoplasmic staining alone requires independent support because HPA supports nucleoplasmic localisation while its additional mitochondrial assignment is uncertain (HPA subcellular). Interpret differences cautiously: the HPA tissue IHC reliability is approved but pending external verification (HPA tissue IHC).
Boster reagents
Best MAFF / Transcription factor MafF IHC Antibodies
A07784-2 has IHC data from human paraffin sections and IF data from A431 cells (catalog image captions); human is the only listed reactivity (catalog: Human).
Real IHC data
Anti-MAFF Antibody ®
Cat # A07784-2
A07784-2 has IHC images from paraffin-embedded human esophageal squamous carcinoma, placenta and lung cancer sections (A07784-2 IHC captions). A07784-2 also has an IF image from A431 cells (A07784-2 IF caption).
Which to pick: Choose A07784-2 for human paraffin-section IHC: its IHC captions show staining at 2 μg/ml after EDTA pH 8.0 retrieval (A07784-2 IHC captions); the fixative is unreported (A07784-2 IHC captions). For IF/ICC, A07784-2 lists both applications and shows IF staining in A431 cells at 5 μg/ml (A07784-2 applications and IF caption). No cross-species option is documented among the supplied products (catalog: Human reactivity only); A07784-2 is rabbit-hosted, with no clone reported (catalog: host and clone).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9ULX9 (MAFF_HUMAN, Transcription factor MafF).
- Human Protein Atlas. MAFF tissue IHC expression (reliability: Approved).
- Human Protein Atlas. MAFF subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the mitochondria..
- Human Protein Atlas. MAFF antibody validation summary (2 antibodies).
- MafF Is Regulated via the circ-ITCH/miR-224-5p Axis and Acts as a Tumor Suppressor in Hepatocellular Carcinoma. Oncology research 2020 — PMC7851502.
- Multi-omics integration reveals hypoxia-driven mechanisms in vascular dementia: a machine learning and single-cell sequencing approach. Annals of medicine and surgery (2012) 2025 — PMC12688720.
- MAFF inhibits angiogenesis in non-small cell lung cancer by suppressing YAP1 nuclear translocation. PeerJ 2025 — PMC12640644.
- Targeted insertion of conditional expression cassettes into the mouse genome using the modified i-PITT. BMC genomics 2024 — PMC11155135.
- PubMed PMID:10527846 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:10591208 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MAFF (Transcription factor MafF). Expected localisation Nuclear staining in tissue (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A07784-2). Validated IHC antibody: A07784-2 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Placenta (Trophoblastic cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human esophageal squamous carcinoma tissue; fixative not specified (datasheet A07784-2); 2. Fixation: Image fixative and duration unreported (datasheet A07784-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A07784-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A07784-2); 8. Primary antibody: Rabbit anti-MAFF, 2-5 μg/ml (datasheet A07784-2); 9. Primary incubation: Overnight at 4 °C (datasheet A07784-2). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Tissue staining awaits external verification (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope coverage is unspecified (UniProt); Regulation: Stress response is annotated; intensity effects are unknown (UniProt). Evidence: UniProt Q9ULX9, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A07784-2, PMC7851502, PMC12640644. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MAFF/immunohistochemistry-ihc-guide.